The prevalence of chronic diseases is increasing worldwide, leading to the demand for effective and accurate treatment. Transfection is used to deliver targeted modified genes to treat several genetic diseases. Transfection method is also used for delivery of CRISPR gene which can enhance adaptive immunity and prevent an individual from different diseases.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-transfection-reagents-and-equipment-market
For instance,
- World Health Organization (WHO) has provided an estimate that by 2020 almost three- quarters of all death worldwide has been accounted due to chronic diseases.
- The centers for disease control and prevention projected that 6 in every 10 adults in the U.S. are suffering from chronic disease.
Data Bridge Market Research analyzes that the Global Transfection Reagent and Equipment Market is expected to grow with a CAGR of 9.6% from 2023 to 2030 and is expected to reach USD 2,284,494.00 thousand by 2030. The reagent and kits segment is projected to propel the market growth as the development of synthetic product is rising worldwide.
Key Findings of the Study
Surging level of investment in development of innovative transfection instruments
The market players operating their business in transfection are continuously investing their money to achieve the best outcome. These companies are also getting funding from third party sources, boosting their activities. Several types of investments are accelerating the research and developmental activities of the transfection products and by time-to-time, new products are adding on to the existing established market.
For instance,
- In April 2020, Polyplus Transfection expanded its partnership with the Warburg Pincus and ArchiMed. Warburg Pincus is one of the equity firm focused on investment. ArchiMed is an equity healthcare specialist who will advance the development and sale of Polyplus' breakthrough solutions. Through this agreement, the company is expected to accelerate the production capacity of several of its major transfection products. This investment allowed the company to access resources form both the companies and to attain a lucrative growth.
The investments done by several companies allowed the development and introduction of new and innovative transfection instruments and reagent in the market. These innovative products have enhanced the transfection efficiency and boosted the manufacturer's credibility in the market. This thus signifies that the surging level of investment is acting as an opportunity for the global transfection reagent and equipment market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2020-2016)
|
|
Quantitative Units
|
Revenue in Thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Products (Reagent & Kits and Instruments), Stage (Research, Preclinical, Clinical Phases, and Commercial), Type (Transient Transfection Reagent and Equipment, Stable Transfection Reagent, and Equipment), Methods (Non-viral Methods and Viral Methods), Types of Molecule (Plasmid DNA, Small Interfering RNA (siRNA), Proteins, DNA Oligonucleotides, Ribonucleoprotein Complexes (RNPs), and Others), Organism (Mammalian Cells, Plants, Fungi, Virus, and Bacteria), Application (In Vitro Application, In Vivo Application, Bioproduction and Others), End User (Biopharma, CROs, (CMOs/CDMOs), Academia, Hospitals, Clinical Labs, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others).
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Switzerland, Russia, Netherlands, Belgium, Turkey, and Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Philippines, Indonesia, and Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt, and Rest of the Middle East and Africa.
|
|
Market Players Covered
|
Mirus Bio LLC. (U.S.), Promega Corporation (U.S.), Polyplus Transfection (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), Lonza (Switzerland), MaxCyte, Inc. (U.S.), Altogen Biosystems (U.S.), SBS Genetech, FUJIFILM Irvine Scientific (A Subsidiary of FUJIFILM Holdings Corporation) (U.S.), Avanti Polar Lipids (A Subsidiary of Croda International Plc) (U.S.), PerkinElmer chemagen Technologie GmbH (A Subsidiary of PerkinElmer Inc.) (Germany), Cytiva (Denmark), Geno Technology Inc., USA (U.S.), R&D Systems, Inc. (U.S.), Takara Bio Inc. (Japan), Thermofisher Scientific Inc. (U.S.), Roche Molecular Systems, Inc. (A Subsidiary of F. Hoffmann-La Roche Ltd), OriGene Technologies, Inc. (U.S.), Applied Biological Materials Inc. (abm)(Canada), Beckman Coulter, Inc. (A Subsidiary of Danaher)(Germany), SignaGen Laboratories (U.S.), Genlantis Inc. (U.S.), Ginkgo Bioworks (U.S.), among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global transfection reagent and equipment market is categorized into nine notable segments which are based on products, stages, methods, type, types of molecule, application, end user, organism, and distribution channel.
- On the basis of products, the global transfection reagent and equipment market is segmented into reagent and kits and instruments. In 2023, the reagent & kits segment is expected to dominate the market with 68.00% market share and is expected to reach USD 1,621,902.15 thousand by 2030 from USD 746,087.43 thousand in 2022, growing with the CAGR of 10.2% in the forecast period of 2023 to 2030.
In 2023, the reagent & kits segment dominating in the global transfection reagent and equipment market as they are used to enhance the efficacy of transfection process in genetic experiments, allowing for substantial research to be conducted in the fields of applied gene therapies.
- On the basis of stage, the global transfection reagent and equipment market is segmented into research, preclinical, clinical phases, and commercial. In 2023, the research segment is expected to dominate the market with 67.57% market share and is expected to reach USD 1,587,801.74 thousand by 2030 from USD 741,387.49 thousand in 2022, growing with the CAGR of 10.0% in the forecast period of 2023 to 2030.
- On the basis of type, the global transfection reagent and equipment market is segmented into transient transfection reagent and equipment and stable transfection reagent and equipment. In 2023, the transient transfection reagent and equipment segment is expected to dominate the market with 66.98% market share and is expected to reach USD 1,631,763.86 thousand by 2030 from USD 734,960.99 thousand in 2022, growing with the CAGR of 10.5% in the forecast period of 2023 to 2030.
- On the basis of methods, the global transfection reagent and equipment market is segmented into non-viral methods and viral methods. In 2023, the non-viral methods segment is expected to dominate the market with 80.11% market share and is expected to reach USD 1,878,036.68 thousand by 2030 from USD 888,178.37 thousand in 2022, growing with the CAGR of 9.8% in the forecast period of 2023 to 2030.
- On the basis of types of molecule, the global transfection reagent and equipment market is segmented into plasmid DNA , small interfering RNA (siRNA), proteins, DNA oligonucleotides, ribonucleoprotein complexes (RNPs), and others. In 2023, the plasmid DNA segment is expected to dominate the market with 40.68% market share and is expected to reach USD 947,757.32 thousand by 2030 from USD 446,338.10 thousand in 2022, growing with the CAGR of 9.9% in the forecast period of 2023 to 2030.
- On the basis of organism, the global transfection reagent and equipment market is segmented into mammalian cells, plants, fungi, virus, and bacteria. In 2023, the mammalian cells segment is expected to dominate the market with 61.31% market share and is expected to reach USD 1,467,931.75 thousand by 2030 from USD 672,694.34 thousand in 2022, growing with the CAGR of 10.2% in the forecast period of 2023 to 2030.
- On the basis of application, the global transfection reagent and equipment market is segmented into in vitro application, in vivo application, bioproduction, and others. In 2023, the in vitro application segment is expected to dominate the market with 70.31% market share and is expected to reach USD 1618,111.84 thousand by 2030 from USD 771,490.24 thousand in 2022, growing with the CAGR of 9.7% in the forecast period.
- On the basis of end user, the global transfection reagent and equipment market is segmented into biopharma, CROs, CMOs/CDMOs, academia, hospitals, clinical labs. In 2023, the biopharma segment is expected to dominate the market with 64.45% market share and is expected to reach USD 1,576,218.28 thousand by 2030 from USD 707,175.24 thousand in 2022, growing with the CAGR of 10.5% in the forecast period of 2023 to 2030.
- On the basis of distribution channel, the global transfection reagent and equipment market is segmented into direct tender, retail sales, and others. In 2023, the direct tender segment is expected to dominate the market with 84.92%market share and is expected to reach USD 1,964,833.46 thousand by 2030 from USD 931,793.32 thousand in 2022, growing with the CAGR of 9.8% in the forecast period of 2023 to 2030.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in the Global transfection reagent and equipment market that include Mirus Bio LLC. (U.S.), Promega Corporation (U.S.), Polyplus Transfection (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), Lonza (Switzerland), MaxCyte, Inc. (U.S.), Altogen Biosystems (U.S.), SBS Genetech, FUJIFILM Irvine Scientific (A Subsidiary of FUJIFILM Holdings Corporation) (U.S.), Avanti Polar Lipids (A Subsidiary of Croda International Plc) (U.S.), PerkinElmer chemagen Technologie GmbH (A Subsidiary of PerkinElmer Inc.) (Germany), Cytiva (Denmark), Geno Technology Inc., USA (U.S.), R&D Systems, Inc. (U.S.), Takara Bio Inc. (Japan), Thermofisher Scientific Inc. (U.S.), Roche Molecular Systems, Inc. (A Subsidiary of F. Hoffmann-La Roche Ltd), OriGene Technologies, Inc. (U.S.), Applied Biological Materials Inc. (abm)(Canada), Beckman Coulter, Inc. (A Subsidiary of Danaher)(Germany), SignaGen Laboratories (U.S.), Genlantis Inc. (U.S.), Ginkgo Bioworks (U.S.), among others.
Market Development
- In August 2021, Mirus Bio expanded the TransIT VirusGen platform for Good Manufacturing Practice (GMP) viral vector production to support cell and gene therapy development, process operations, and commercial production. The extension, referred to as TransIT VirusGen GMP Transfection Reagent is designed to improve the packaging and delivery of vector DNA to suspension and adherent HEK 293 cell types to improve the production of recombinant adeno-associated viruses and lentiviral vectors.
- In April 2021, BOC Sciences announced the launch of two in vivo RNA transfection kits, namely siRNA in vivo transfection kits and mRNA in vivo transfection kits, suitable for in vivo transfection of siRNA and mRNA, respectively.
- In November 2020, Eli Lilly and Company and Precision BioSciences Inc. collaborated to use Precizo's proprietary ARCUS genome editing platform to research and develop potential in-vivo therapies for genetic diseases. Duchenne muscular dystrophy (DMD) and two other secreted gene targets were initially focused on.
- In March 2020, Thermo Fischer Scientific Inc. invested more than USD 475.00 million to meet the increasing demand for biologics development and manufacturing. This investment by the company and the investment made in 2019 totaled USD 800.00 million for boosting the biopharmaceutical product manufacturing.
- In July 2019, FUJIFILM Irvine Scientific (a subsidiary of FUJIFILM Holdings Corporation) opened a new manufacturing facility in Europe. The company has opened this manufacturing site to enhance cell and gene therapy production involving transfection products, among others. This initiative by the company accelerated the company's growth.
Regional Analysis
Geographically, the countries covered in the transfection reagent and equipment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in transfection reagent and equipment market during the forecast period 2023-2030
In 2023, North America dominated the transfection reagent and equipment market owing to the higher level of investments by U.S. manufacturers and increasing prevalence of chronic diseases in U.S. North America will continue to dominate the transfection reagent and equipment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing adoption of advanced technology and launch of new products in this region. Additionally, the increasing number of cases of chronic problems and the rising development of synethetic biology products are expected to further enhance the market's growth rate in this region.
Asia-Pacific is estimated to be the fastest growing region in transfection reagent and equipment market the forecast period 2023-2030
Asia-Pacific is expected to grow during the forecast period due to the presence of major market players and rapid development of medical facilities in emerging economies in this region. In addition to this, rising level of healthcare expenditure and increasing per-capita income are expected propel the market's growth rate in this region.
For more detailed information about the transfection reagent and equipment market report, click here – https://www.databridgemarketresearch.com/reports/global-transfection-reagents-and-equipment-market
